

# Vicent Hernandez Ramirez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7950420/publications.pdf>

Version: 2024-02-01

89  
papers

4,281  
citations

159585

30  
h-index

110387

64  
g-index

92  
all docs

92  
docs citations

92  
times ranked

5642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population-based universal screening for CRC: Secondary prevention. , 2022, , 45-56.		0
2	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	2.4	8
3	Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of Epi-IBD 2011 study in the Vigo area. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.3	1
4	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, 15, 1846-1851.	1.3	39
5	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. Journal of Clinical Medicine, 2021, 10, 2885.	2.4	38
6	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€”What, Why, and How. Journal of Crohn's and Colitis, 2021, 15, 1410-1430.	1.3	28
7	The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move. Revista Espanola De Enfermedades Digestivas, 2021, 113, 153-154.	0.3	0
8	Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology, 2020, 18, 1216-1223.e2.	4.4	22
9	The use of 5-aminosalicylate for patients with Crohnâ€™s disease in a prospective European inception cohort with 5 years follow-up â€” an Epi-IBD study. United European Gastroenterology Journal, 2020, 8, 949-960.	3.8	17
10	Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. Diagnostics, 2020, 10, 437.	2.6	7
11	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology and Hepatology, 2020, 5, 454-464.	8.1	76
12	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. Journal of Crohn's and Colitis, 2020, 14, 1290-1298.	1.3	5
13	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1492-1500.	1.3	37
14	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00003.	2.5	53
15	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohortâ€”An Epi-IBD Study. Journal of Crohn's and Colitis, 2019, 13, 198-208.	1.3	100
16	Natural disease course of Crohnâ€™s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut, 2019, 68, 423-433.	12.1	176
17	Effect of aspirin on the diagnostic accuracy of the faecal immunochemical test for colorectal advanced neoplasia. United European Gastroenterology Journal, 2018, 6, 123-130.	3.8	9
18	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detectionâ€”surveillance paradox. United European Gastroenterology Journal, 2018, 6, 622-629.	3.8	16

#	ARTICLE	IF	CITATIONS
19	Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial. United European Gastroenterology Journal, 2018, 6, 1527-1537.	3.8	7
20	The right colon challenge. Revista Espanola De Enfermedades Digestivas, 2018, 110, 135-137.	0.3	0
21	FACTORS RELATED TO INADEQUATE COLON CLEANSING. , 2018, 50, .		0
22	No controversial role of alcohol consumption in the development of inflammatory bowel diseases. European Journal of Clinical Nutrition, 2018, 72, 305-306.	2.9	3
23	European Crohn's and Colitis Organisation Topical Review on environmental factors in IBD. Journal of Crohn's and Colitis, 2017, 11, jjw223.	1.3	27
24	No association of alcohol use and the risk of ulcerative colitis or Crohn's disease: data from a European Prospective cohort study (EPIC). European Journal of Clinical Nutrition, 2017, 71, 512-518.	2.9	53
25	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort: An ECCO-EpiCom Study. Journal of Crohn's and Colitis, 2017, 11, 1213-1222.	1.3	23
26	Correlation between adenoma detection rate in colonoscopy and fecal immunochemical testing based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	3.8	46
27	Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention. Nutrients, 2017, 9, 962.	4.1	116
28	Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index. Revista Espanola De Enfermedades Digestivas, 2017, 109, 542-551.	0.3	7
29	Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer. Scientific Reports, 2016, 6, 26703.	3.3	12
30	Mo1685 Rate of Detection of Serrated Lesions in Proximal Colon by Simulated Sigmoidoscopy: Comparison With Colonoscopy and Faecal Immunochemical Testing in a Multicentre, Pragmatic, Randomised Controlled Trial. Gastroenterology, 2016, 150, S750-S751.	1.3	1
31	Mo1821 Medical Therapy, Surgery and Hospitalization Rates During the 2-and 3-Year Follow-Up of the 2011 ECCO-EpiCom Cohort. Gastroenterology, 2016, 150, S785.	1.3	0
32	Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine, 2016, 14, 128.	5.5	56
33	Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy, 2016, 48, 995-1002.	1.8	21
34	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. European Journal of Gastroenterology and Hepatology, 2016, 28, 802-806.	1.6	7
35	Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy, 2016, 48, 241-247.	1.8	42
36	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.9	23

#	ARTICLE	IF	CITATIONS
37	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	29
38	Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening. <i>Scientific Reports</i> , 2015, 5, 13030.	3.3	19
39	Diagnostic Performance of Fecal Immunochemical Test and Sigmoidoscopy for Advanced Right-Sided Colorectal Neoplasms. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1424-1432.	2.3	11
40	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-EpiCom Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 747-753.	1.3	38
41	Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naïve Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 430-435.	1.6	18
42	Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. <i>Gastroenterología Y Hepatología</i> , 2015, 38, 534-540.	0.5	21
43	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 945-965.	1.3	328
44	Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test. <i>British Journal of Cancer</i> , 2015, 112, 375-381.	6.4	21
45	Prevention of post-operative recurrence in Crohn's disease. Are we ready for a treat-to-target strategy?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 583-5.	0.3	0
46	Effect of oral anticoagulants on the outcome of faecal immunochemical test. <i>British Journal of Cancer</i> , 2014, 110, 1334-1337.	6.4	30
47	Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening. <i>United European Gastroenterology Journal</i> , 2014, 2, 522-529.	3.8	19
48	East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. <i>Gut</i> , 2014, 63, 588-597.	12.1	321
49	Fecal immunochemical test accuracy in familial risk colorectal cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 367-375.	5.1	28
50	Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 36-46.	1.9	71
51	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1708-1716.e4.	4.4	13
52	OP008 The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S5-S6.	1.3	0
53	Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe – An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 607-616.	1.3	81
54	Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1506-1515.	1.3	82

#	ARTICLE	IF	CITATIONS
55	Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. <i>Cancer Causes and Control</i> , 2014, 25, 985-997.	1.8	31
56	Characteristics of Adenomas Detected by Fecal Immunochemical Test in Colorectal Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1884-1892.	2.5	19
57	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 5-18.	1.3	110
58	P305 Tuberculosis infection in inflammatory bowel disease patients after anti-TNF therapy in a high tuberculosis prevalence rate area. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S191-S192.	1.3	0
59	Fecal immunochemical test accuracy in average-risk colorectal cancer screening. <i>World Journal of Gastroenterology</i> , 2014, 20, 1038.	3.3	54
60	Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test. <i>Mayo Clinic Proceedings</i> , 2013, 88, 683-689.	3.0	24
61	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 381-389.e1.	1.0	125
62	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 333-341.e1.	1.0	62
63	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. <i>Journal of the National Cancer Institute</i> , 2013, 105, 878-886.	6.3	25
64	Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility. <i>PLoS ONE</i> , 2013, 8, e72091.	2.5	19
65	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. <i>New England Journal of Medicine</i> , 2012, 366, 697-706.	27.0	763
66	Erratum to "Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study" [ <i>J Crohns Colitis</i> (2011) 5, 430-442]. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 132-133.	1.3	1
67	Mo1004 Is There an East-West Gradient in the Incidence of IBD in Europe? and Further Far East in China? First Results From the Epicom Study. <i>Gastroenterology</i> , 2012, 142, S-569-S-570.	1.3	1
68	Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. <i>Journal of Gastroenterology</i> , 2012, 47, 359-365.	5.1	31
69	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 275-283.	3.7	102
70	Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. <i>Annals of Gastroenterology</i> , 2012, 25, 193-200.	0.6	6
71	Participaci3n en programas de cribado de c4ncer colorrectal: qu factores influyen?. <i>Gastroenterol3gia Y Hepatol3gia Continuada</i> , 2011, 10, 87-90.	0.0	1
72	Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 430-442.	1.3	40

#	ARTICLE	IF	CITATIONS
73	Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients. <i>Gastroenterology</i> , 2011, 140, S-109.	1.3	16
74	Malondialdehyde in early phase of acute pancreatitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 563-569.	0.3	10
75	Post-Marketing Health Technology Monitoring. The Analysis of an Experience from a Clinical Perspective. <i>Frontiers in Pharmacology</i> , 2011, 2, 45.	3.5	1
76	Ulcerative colitis in northern Portugal and Galicia in Spain. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1227-1238.	1.9	27
77	W1333 Leukocyte-Apheresis for Steroid-Refractory Ulcerative Colitis. Results of a Nationwide Spanish Registry. <i>Gastroenterology</i> , 2010, 138, S-701.	1.3	2
78	W1334 Leukocyte-Apheresis for Steroid-Dependent Ulcerative Colitis. Results of a Nationwide Spanish Registry. <i>Gastroenterology</i> , 2010, 138, S-701.	1.3	0
79	Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: The RECLICU Study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 629-636.	1.3	24
80	Recurrence of Acute Gallstone Pancreatitis and Relationship with Cholecystectomy or Endoscopic Sphincterotomy. <i>American Journal of Gastroenterology</i> , 2004, 99, 2417-2423.	0.4	104
81	Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. <i>Gastroenterology</i> , 2004, 126, 57-62.	1.3	251
82	Unstimulated salivary flow rate, pH and buffer capacity of saliva in healthy volunteers. <i>Revista Espanola De Enfermedades Digestivas</i> , 2004, 96, 773-83.	0.3	130
83	Diagnostic efficacy of magnetic resonance cholangiopancreatography after secretin stimulation (MRCP-S) in pancreatic disease. <i>Gastroenterology</i> , 2003, 124, A399.	1.3	0
84	Predictive value of balloon expulsion test and symptom diary for selecting constipated patients without pelvic floor dyssynergia. <i>Gastroenterology</i> , 2003, 124, A683.	1.3	0
85	Bacterial overgrowth and orocecal transit time in inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A192.	1.3	0
86	Carbohydrate malabsorption and/or intolerance in inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A195.	1.3	0
87	Dental and periodontal lesions in patients with gastro-oesophageal reflux disease. <i>Digestive and Liver Disease</i> , 2003, 35, 461-467.	0.9	87
88	Clinical features and prognostic factors of recurrent acute biliary pancreatitis. <i>Gastroenterology</i> , 2003, 124, A399-A400.	1.3	0
89	Late recurrence of anal fissure after conservative therapy with botulinum toxin. <i>Gastroenterology</i> , 2001, 120, A398.	1.3	0